"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.
Saturday, 18 April 2020
U.S. Army Receives Remdesivir at No Cost
Back in March, the U.S. Army signed a deal with Gilead Sciences to receive Remdesivir at no cost to treat Covid-19. This is especially important given the recent study demonstrating Remdesivir as a potential effective treatment for Covid-19. The Military Times discusses the deal as well as work on a vaccine which started in January, here.
Posted by Mike Mireles at 04:56:00
Labels: coronavirus, covid-19, gilead sciences, us army, Vaccine
Subscribe to: Post Comments (Atom)
Post a Comment